Creative Biolabs is one of the well-recognized experts who are skilled in applying the SELEX platform for aptamer development. Equipped with rich experience in aptamer screening and world-leading live-animal-based-SELEX platform, we provide one-stop DNA/RNA aptamers selection services targeting certain tissues or organs of a living animal.
Introduction of Live-animal-based-SELEX
Live-animal-based-SELEX, also known as in vivo-SELEX, is developed to overcome some problems associated with in vitro protein-SELEX and cell-SELEX. Aptamers selected by protein-SELEX or cell-SELEX have shown low toxicity and immunogenicity, which greatly hinder the application of the aptamers in disease diagnosis and therapy. In vivo-SELEX is applied to select functional aptamers targeting organs or tissues of a living animal, which greatly improves the affinity and specificity of aptamers in vivo. The in vivo-SELEX starts with the construction of a random library of RNA or DNA aptamers modified by 2´-fluoropyrimidine and then systemically injects the library into a living animal. Certain aptamers bind to the desired target organs or tissues and unbound aptamers are eliminated by the kidney. Whereafter, the target organs or tissues are harvested for the extraction of bound aptamers. The extracted aptamers are amplified by PCR for the next round of screening. After 15~20 rounds of screening, the aptamers specific to target organs or tissues are enriched and then identified by high-throughput sequencing. In vivo-SELEX has been employed to develop DNA/RNA aptamers targeting brain tissues and certain tumor tissues such as intrahepatic colorectal cancer and lymphoma.
Fig. 1 Schematic presentation of cell-internalization and in vivo SELEX procedure.1
Services
At Creative Biolabs, we are committed to providing the best and affordable services to promote aptamer development in a short time. Our service package includes aptamer screening, conjugation, modifications, characterization, and in vitro and in vivo analysis. Equipped with rich expertise and a first-in-class technical platform, we are committed to providing unparalleled in vivo-SELEX services for aptamer development. The service flow is as follows:
Advantages
-
Well-established SELEX platform for aptamer development
-
One-stop services from scheme design to reliable data delivery
-
Customized services according to your project's requirement
-
Rich expertise in aptamer development
-
Comprehensive and all-round guidance in real-time
-
Shorter detective cycle
If you are interested in our live-animal-based-SELEX service for aptamer development, please contact us for more details.
Reference
-
Liu, Mei, et al. "Aptamer selection and applications for breast cancer diagnostics and therapy." Journal of nanobiotechnology 15.1 (2017): 1-16.
Related Product
Questions & Answer
A: Live animal-based SELEX offers the advantage of selecting aptamers that are functionally relevant in a complex biological environment. It allows for the identification of aptamers that can modulate complement activity under physiological conditions, providing more promising candidates for therapeutic applications.
A: Specificity and selectivity are typically ensured by using stringent selection conditions and multiple rounds of selection. Negative selection steps can also be employed to remove sequences that bind non-specifically to other components in the living organism.
A: Future research may focus on enhancing the efficiency of aptamer selection, broadening the range of target molecules, and exploring novel applications in diagnostics and therapeutics.
For Research Use Only.
Related Sections:
